Cipla Uncorks Peptide Injectables Pipeline
Indian Giant Also Eyes Partnering Opportunities For Monkeypox
Executive Summary
Cipla readies scale-up in peptide injectables with five filings in the US and gears for upcoming high-value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.
You may also be interested in...
Lannett Comes Out Firing On Insulin Pipeline Prospects
Lannett continued to talk up its prospects of launching numerous low-competition, high-value products in the coming years – as it disclosed another sizeable loss for its 2022/23 financial year.
Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside
Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.
EMA To Track Monkeypox Medicines Stock & Boost Emergency Task Force Output
The European Medicines Agency is taking more actions to tackle monkeypox now that the disease has been declared a public health emergency.